Contact Us   |   Sign In   |   Join ISCT
News & Press: Breaking News

Registration Open for Pre-Conference Workshop at ISCT Europe 2015 Regional Meeting

Monday, August 10, 2015  
Share |

MSC & Cancer: Trojan Horses for Novel Cancer Therapeutics or Fast Food For Tumors

Wednesday September 23rd
1300 - 1900
Hotel Barceló Sevilla Renacimiento

Workshop Co-Chairs: Khalid Shah, MS, PhD & Massimo Dominici, MD

 

Objectives of the Workshop:

  1. Highlight the roles of MSC in tumor microenvironment and in cancer immunity
  2. Describe the role of naive MSC as Tumor Promoting/Suppressing agents in in vivo models
  3. Dissect the possible technical limitations/advantages (in vitro and in vivo) in addressing the pro- and anti-tumorigenic functions of MSC in pre-clinical settings
  4. Present MSC-gene modified models in the context of several cancer types (brain, lungs, pancreas, sarcomas and more)
  5. Promote potential interactions between relevant investigators in the field
  6. Build academic-industry partnerships for MSC based approaches in cancer patients

The workshop is divided into 3 sessions:

  • SESSION 1: HAMBURGERS OR TROJAN HORSES: THAT IS THE PROBLEM
  • SESSION 2: THE TRAIL TO CLINIC
  • SESSION 3: THE EARLY CLINICAL EVIDENCES

Confirmed Speakers and Tentative Topics:

  • Antoine E Karnoub, PhD (USA): Role of MSC-regulated micRNAs in tumor progression
  • Julia Houthuijzen, MSc (Netherlands)Role of MSC in anti-cancer drug resistance and tumor progression
  • Giulio Alessandri, PhD (Italy): MSC loaded with traditional drugs for tumor therapy
  • Lucia Kucerova, PhD (Slovacchia): MSC and pro-drugs activators in cancers
  • Giulia GrisendiPhD (Italy): MSC in pancreatic adenocarcinoma and sarcoma
  • Daniel Weiss, MD, PhD (USA): MSC in deathly lung cancers: the mesothelioma model
  • Khalid Shah, MS, PhD (USA): Receptor targeted and encapsulated MSC for tumors in the brain
  • Samuel Janes, MBBS, MRCP, MSc, PhD (UK): MSC towards the clinic for lung cancers

For program and registration information click here.